Arcturus Therapeutics Holdings, Inc. (ARCT)
7.46
-0.06
(-0.80%)
USD |
NASDAQ |
Dec 12, 16:00
7.45
-0.01
(-0.13%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Research and Development Expense (TTM): 101.81M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Inovio Pharmaceuticals, Inc. | 55.38M |
| Novavax, Inc. | 369.02M |
| Sangamo Therapeutics, Inc. | 104.77M |
| Capricor Therapeutics, Inc. | 74.99M |
| AIM ImmunoTech, Inc. | 3.826M |